Skip to content

How thoracic wall blocks affect heart surgery: a study assessing their effectiveness

Chest Wall Blocks in Cardiac Surgery: A randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3hdzygd
Enrollment
Unknown
Registered
2026-01-28
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve Block

Interventions

This is a two-arm randomized controlled clinical trial. A total of 92 people who meet the eligibility criteria will be probabilistically allocated to one group or the other. Neither the researchers ev
s discretion, Ketamine, rocuronium, etomidate, and maintenance of anesthesia with 2 to 3 percent sevoflurane. Information will be collected on the incidence of postoperative pain, opioid consumption,

Sponsors

Instituto das pequenas missionárias da Maria Imaculada
Lead Sponsor
Instituto das pequenas missionárias da Maria Imaculada
Collaborator

Eligibility

Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adult patients aged between 25 and 80 years ; both sexes ; elective cardiac surgery ; median sternotomy (valve replacement, valvuloplasty or myocardial revascularization)

Exclusion criteria

Exclusion criteria: Extracorporeal circulation (ECC) time: greater than 120 minutes ; perioperative complications: primarily surgical, which may directly impact the analyzed outcomes ; diseases with pain hypersensitivity: conditions that may significantly alter pain perception and opioid consumption (e.g., fibromyalgia, neurological diseases that impact pain sensitivity) ; reoperative surgeries: pain and recovery time may differ significantly ; coagulation disorders that may increase the risk of hematomas in regional blocks ; allergy or contraindication to local anesthetics or adjuvants; inability to communicate and assess: patients who cannot express or report their pain reliably (e.g., severe neurological disorders, cognitive impairment)

Design outcomes

Primary

MeasureTime frame
A reduction in opioid consumption is expected during and immediately after surgery

Secondary

MeasureTime frame
A reduction in mechanical ventilation time is expected between the groups;It is expected that there will be a reduction in the length of stay in the intensive care unit and hospital;A reduction in the use of vasoactive drugs is expected;It is expected that there will be a reduction in the incidence of adverse effects from opioids;A reduction in the occurrence of respiratory complications is expected;A reduction in the occurrence of arrhythmias is expected;A reduction in postoperative pain levels is expected 6, 12, and 24 hours post-surgery

Countries

Brazil

Contacts

Public ContactLucas Fuentes

Hospital e Maternidade Marieta Konder Bornhausen

lucasveronesef@gmail.com+55(17)991227407

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 7, 2026